Nurix Therapeutics NRIX
NASDAQ NRIX
$22.99 -0.35 (-1.50%)
At close: Oct 2, 2026 · 4:00 PM EDT

Nurix Therapeutics (NRIX) Gains from Sales and Divestitures (2022 - 2026)

Updated

Nurix Therapeutics (NRIX) reported Gains from Sales and Divestitures of -$160,000 for fiscal Q1 2026 (quarter ended Feb 28, 2026).

Analysis

Nurix Therapeutics (NRIX) Gains from Sales and Divestitures (2022 - 2026) Analysis & Trends

For FY2025 (ended Nov 30, 2025), Nurix Therapeutics posted Gains from Sales and Divestitures of -$89,000.

  • By fiscal year, Gains from Sales and Divestitures came in at -$31,000 in FY2024, -$556,000 in FY2023, -$9,000 in FY2022 and -$128,000 in FY2021.
  • The fiscal Q1 2026 figure ranks as the highest quarterly Gains from Sales and Divestitures since fiscal Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Nurix Therapeutics 2.38 Bn 378.07 Mn -
Historic Data

Historic Data

Download Data
DateValue
Feb 28, 2026 -160,000.00
Nov 30, 2024 -31,000.00
Nov 30, 2023 -12,000.00
Aug 31, 2023 -448,000.00
May 31, 2023 -40,000.00
Feb 28, 2023 -56,000.00
May 31, 2022 -9,000.00
API Access

Nurix Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=NRIX&period=max&api_key=YOUR_API_KEY